AllSquare Wealth Management’s Cellectar Biosciences CLRB Stock Holding History

AllSquare Wealth Management’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1	Closed	-$6	–	540
2025 Q1	$6	Hold	1	–	–	﹤0.01%	534
2024 Q4	$5	Hold	1	–	–	﹤0.01%	536
2024 Q3	$39	Hold	1	–	–	﹤0.01%	534
2024 Q2	$45	Hold	1	–	–	﹤0.01%	527
2024 Q1	$72	Hold	1	–	–	﹤0.01%	523
2023 Q4	$50	Hold	1	–	–	﹤0.01%	527
2023 Q3	$48	Hold	1	–	–	﹤0.01%	534
2023 Q2	$27	Hold	1	–	–	﹤0.01%	559
2023 Q1	$26	Hold	1	–	–	﹤0.01%	552
2022 Q4	$31	Hold	1	–	–	﹤0.01%	527
2022 Q3	$0	Hold	1	–	–	﹤0.01%	504
2022 Q2	$0	Hold	1	–	–	﹤0.01%	506
2022 Q1	$0	Hold	1	–	–	﹤0.01%	507
2021 Q4	$0	Hold	1	–	–	﹤0.01%	494
2021 Q3	$0	Hold	1	–	–	﹤0.01%	483
2021 Q2	$0	Hold	1	–	–	﹤0.01%	498
2021 Q1	$0	Hold	1	–	–	﹤0.01%	494
2020 Q4	$0	Hold	1	–	–	﹤0.01%	460
2020 Q3	$0	Hold	1	–	–	﹤0.01%	466
2020 Q2	$0	Hold	1	–	–	﹤0.01%	468
2020 Q1	$0	Hold	1	–	–	﹤0.01%	458
2019 Q4	$0	Hold	1	–	–	﹤0.01%	450
2019 Q3	$0	Hold	1	–	–	﹤0.01%	454
2019 Q2	$0	Hold	1	–	–	﹤0.01%	459
2019 Q1	$0	Buy	+1	New	+$609	﹤0.01%	464

Other funds holding CLRB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

RCA

Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

AllSquare Wealth Management's CLRB Position: Q2 2025 in Review

AllSquare Wealth Management sold out of Cellectar Biosciences (CLRB) in Q2 2025, closing a stake of 1 share — an estimated $6 sold.

AllSquare Wealth Management first reported a position in CLRB in Q1 2019 and held it in 25 quarters. The position peaked at $72 in Q1 2024. 19 funds tracked by Wall St. Rank hold CLRB as of Q2 2025.

AllSquare Wealth Management reported no remaining Cellectar Biosciences position as of Q2 2025 after selling out during the quarter.
AllSquare Wealth Management sold 1 Cellectar Biosciences share in Q2 2025, an estimated $6.
AllSquare Wealth Management first reported a position in Cellectar Biosciences in Q1 2019 and held it in 25 quarters.
AllSquare Wealth Management's Cellectar Biosciences position peaked at $72 in Q1 2024.
19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2025.

Based on AllSquare Wealth Management's 13F filing for Q2 2025, filed 14 Aug 2025.